A 2-part Phase 1b Clinical Trial to Evaluate CRB-913 in People with Obesity
Phase 1
252
about 8 months
18–75
15 sites in AL, AZ, CA +7
What this study is about
This trial is testing the safety of a new drug called CRB-913. It has two parts: Part 1 measures how the drug affects people's bodies, and Part 2 compares CRB-913 to a placebo (inactive pill) over 12 weeks to see if it helps with weight loss and blood levels of the drug.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CRB-913
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part 1: To evaluate the PK of a single dose of CRB-913 - Cmax, Part 1: To evaluate the PK of a single dose of CRB-913 - T1/2, Part 1: To evaluate the PK of a single dose of CRB-913 - Tmax, Part 2: To evaluate the safety of CRB-913 - TEAE
Secondary: Part 1: To evaluate the safety of a single dose of CRB-913 - TEAE, Part 2: To evaluate the PK of CRB-913 - Cmax, Part 2: To evaluate the PK of CRB-913 - Tmax